Trial Profile
Regorafinib escalation for colorectal cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Feb 2020
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms RECC study
- 25 Jan 2020 Results (n=57) assessing safety and efficacy of regorafenib in an Asian population, presented at the 2020 Gastrointestinal Cancers Symposium.
- 04 Oct 2017 New trial record